Neurol. praxi. 2012;13(3):140-145

Parkinsonian syndrome and extrapyramidal symptoms in neurodegenerative

MUDr.Petra Bártová, Ph.D.
Neurologická klinika FN Ostrava

diseases associated with disorders of iron metabolism

Iron plays a significant role in the human body. Neurodegeneration with brain iron accumulation (NBIA) characterizes a heterogeneous

group of neurodegenerative diseases associated with iron accumulation in the central areas of the brain. The most common disease of

this group is pantothenate kinase-associated neurodegeneration (PKAN), an autosomal recessive disease characterized by a mutation

in the PANK2 gene and impaired metabolism of coenzyme A. Also included here are phospholipase A2-associated neurodegeneration

caused by a mutation in the PLA2G6 gene and conditions, such as neuroferritinopathy, aceruloplasminaemia, and others, that currently

belong to the NBIA group. Iron metabolism is also linked to other systemic conditions, e.g. haemochromatosis. The paper presents the

characteristic features, clinical manifestations as well as the options for diagnosis and differential diagnosis of these conditions.

aceruloplasminaemia, haemochromatosis.

Keywords: neurodegeneration with brain iron accumulation, pantothenate kinase-associated neurodegeneration, neuroferritinopathy,

Published: May 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bártová P. Parkinsonian syndrome and extrapyramidal symptoms in neurodegenerative. Neurol. praxi. 2012;13(3):140-145.
Download citation

References

  1. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, Whote LR, Aasly JO. Prevalence of haemachromatosis gene mutations in Parkinson´s disease. J Neurol Neurosurg Psychiatry 2007; 78: 315-317. Go to original source... Go to PubMed...
  2. Beutler E. Hemochromatosis: genetics and pathophysiology. Annu rev. Med 2006; 57: 331-347. Go to original source... Go to PubMed...
  3. Castello DJ, Walsh SL, Harrington HJ, Walsh CH. Concurrent hereditary hemochromatosis and idiopathic Parkinson´s disease: a case report series. J Neurol Neurosurg Psychiatry 2004; 75: 631-633. Go to original source... Go to PubMed...
  4. Crompton DE, Chinnery PF, Fey C, Curtis ARJ, Morris CHM, Kierstan J, Burt A, Young F, Coulthard A, Curtis A, Ince PG, Bates D, Jackson MJ, Burn J. Neuroferritinopathy: A window on the role of iron in neurodegeneration blood cells. Molecules, and Diseases 2002; 29(3): 522-531. Go to original source... Go to PubMed...
  5. Curtis AR, FeyC, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28: 350-354. Go to original source... Go to PubMed...
  6. Dekker MCJ, Giesbergen PC, Njajou OT, Swieten JC, Hofman A, Breler MMB, Duijn CM. Mutations in hemochromatosis gene (HFE), Parkinson´s disease and parkinsonism. Neuroscience Letters 2003; 348: 117-119. Go to original source... Go to PubMed...
  7. Egan RA, Weleber RG, Hogarth P, Gregory A, Coryell J, Westaway SK, Gitschier J, Das S, Hayflick SJ. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly HallervordenSpatz syndrome). Am J Ophthalmol 2005; 140(2): 267-274. Go to original source... Go to PubMed...
  8. Finkenstedt A, Wolf E, Höfner E, Gasser BI, Bösch S, Bakry R, Creus M, Kremser M, Schocke M, Theurl M, Moser P, Schranz M, Bonn G, Poewe W, Vogel W, Janecke WA, Zoller H. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 2010; 53(6): 1101-1107. Go to original source... Go to PubMed...
  9. Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Sommer U, Zeiler B, Becker G, Riess O, Berg D. Screening for mutations of the ferritin light and heavy genes in Parkinson´s disease patients with hyperechogenicity of the substatnia nigra. Neuroscience letters 2003; 352: 53-56. Go to original source... Go to PubMed...
  10. Gregory A, Hayflick SJ. Genetics of Neurodegeneration with Brain Iron Accumulation. Curr Neurol Neurosci Rep 2011; 11: 254-261. Go to original source... Go to PubMed...
  11. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46: 73-80. Go to original source... Go to PubMed...
  12. Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot, C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology 2008; 71: 1042-1049. Go to original source... Go to PubMed...
  13. Guillerman RP. The eye of the tiger sign. Radiology 2000; 217(3), 895-896. Go to original source... Go to PubMed...
  14. Hartig MB, Iuso A, Haack T, Kmiec T, Jurkiewicz E, Heim K, Roeber S, Tarabin V, Dusi S, Krajewska-Walasek M, Jozwiak S, Hempel M, Winkelmann J, Elstner M, Oexle K, Klopstock T, Mueller-Felber W, Gasser T, Trenkwalder C, Tiranti V, Kretzschmar H, Schmitz G, Strom TM, Meitinger T, Prokisch H. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet. 2011 Oct 7; 89(4): 543-550. Go to original source... Go to PubMed...
  15. Hochstrasser H, Baeur P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004; 63: 1912-1917. Go to original source... Go to PubMed...
  16. Chang MH, Hung WL, Liao YCH, Lee YCH, Hsiech PF. Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy. J Neural Transm 2009; 116: 861-866. Go to original source... Go to PubMed...
  17. Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase associated neurodegeneration. Neurology 2002; 58(11): 1673-1674. Go to original source... Go to PubMed...
  18. Chinnery PF, Curtis AR, Fey C, Coulthard A, Crompton D, Curtis A, Lomb?s A, Burn I. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet 2003; 40: 69. Go to original source... Go to PubMed...
  19. Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 5rd edition. Philadelphia: William Wilkins, 2007: 562-567.
  20. Kastner, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992; 59(3): 1080-1089. Go to original source... Go to PubMed...
  21. Klempíř J, Mikulenková D, Písačka M, Klempířová O. Diferenciální diagnostika neuroakantocytos. Cesk Slov Neurol N 2009; 72(1): 24-29.
  22. Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 2004; 53: 756-758. Go to original source... Go to PubMed...
  23. Martinez-Heranndez R, Mountes S, Higuera-Callleja J, Rios C. Plasma ceruloplasmin ferroxidase activity cerrelates with substatnia nigra sonographic area in Parkinsons disease patients. Movement Dis 2007; 22(Suppl.16): P640.
  24. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, Wilmot B, Kramer P, Gitschier J, Maher ER, Hayflick SJ. PLA2G6, encoding a phospholipase A (2), is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38: 752-754. Go to original source... Go to PubMed...
  25. Mubaidin A, Roberts E, Hampshire D, Dehyyat M, Shurbaji A, Mubaidien M, Jamil A, Al-Din A, Kurdi A, Woods CG. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet 2003; 40: 543-546. Go to original source... Go to PubMed...
  26. McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenk JF, Zimmerman EA, Shang H, Miyajima H, Chinnery PF. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008 Apr 29; 70(18): 1614-1619. Go to original source... Go to PubMed...
  27. Petrleničová D, Gmitterová K, Uhrín I, Benetin J, Valkovič P. Neurodegenerácia asociovaná s pantotenátkinázou - kazuistika. Cesk Slov Neurol N 2011; 74/107(2): 201-204.
  28. Rouault TA, Cooperman S. Brain Iron Metabolism. Semin Pediatr Neurol 2006; 13: 142-148. Go to original source... Go to PubMed...
  29. Salazar J, Mena N, Nunez MT. Iron dyshomeostasis in Parkinson´s disease. J Neural Transm Suppl. 2006; (71): 205-213. Go to original source... Go to PubMed...
  30. Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): An update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012; 27(1): 42-53. Go to original source... Go to PubMed...
  31. Taylor TD, Litt M, Kramer P, Angelini L, Nardocci N, Davis S, Pineda M, Hattori H, Flett PJ, Cilio MR, Bertini E, Hayflick SJ. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12. 3-p13. Nat Genet 1996; 14: 479-481. Go to original source... Go to PubMed...
  32. Timmermann L, Pauls KA, Wieland K, Jech R, Kurlemann G, Sharma N, Gill SS, Haenggeli CA, Hayflick SJ, Hogarth P, Leenders KL, Limousin P, Malanga CJ, Moro E, Ostrem JL, Revilla FJ, Santens P, Schnitzler A, Tisch S, Valldeoriola F, Vesper J, Volkmann J, Woitalla D, Peker S. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133(3): 701-712. Go to original source... Go to PubMed...
  33. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Rev 2005; 49(3): 633-640. Go to original source... Go to PubMed...
  34. Vongsuvanh R, Hooper AJ, Coakley JC, Macdessi JS, O´Loughlin EV, Burnett JR, Gaskin KJ. Novel mutations in abetalipoproteinaemia and homozygous familial hypobetalipoproteinaemia. J Inherit Metab Dis 2007; 30: 990. Go to original source... Go to PubMed...
  35. Zecca L, Berg D, Atzberger T, Ruprecht P, Rausch WD, Musico M, Tampellini D, Riederer P, Gerlach M. In vivo detection of Iron and Neuromelanin by transcranial sonography: a new aproach for early detection of substantia nigra damage. Mov Disord. 2005; 20(10): 1278-1285. Go to original source... Go to PubMed...
  36. Zhou B, Westaway SK, Livinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345-349. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.